Salvianolic acid A

Name: Salvianolic acid A
Brand: MedChemExpress
SKU: HY-N0318
Rating: 5.0 (11 reviews)

Cat. No.: HY-N0318 Purity: 99.72%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.

For research use only. We do not sell to patients.

CAS No. : 96574-01-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Salvianolic acid A:

Salvianolic acid A (Standard) In-stock

11 Publications Citing Use of MCE Salvianolic acid A

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Cell Imaging/Staining

PK/PD Analysis

Bio/Physico-chemical Assay

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]; Body weight changes in Female BALB/c mice aged 6–8 weeks after treatment with 20 mg/kg of Salvianolic acid A (SAA), Chebulinic Acid, Tannic acid, or Punicalagin via i.g. upon challenge once daily for 3 days. 300 mg/kg T-705 administered via i.g. was used as a positive control.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]; T-705 and SAA significantly reduced viral copies in the liver in Female BALB/c mice aged 6–8 weeks after treatment with 20 mg/kg of Salvianolic acid A (SAA), Chebulinic Acid, Tannic acid, or Punicalagin via i.g. upon challenge once daily for 3 days. 300 mg/kg T-705 administered via i.g. was used as a positive control.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]; Viral copies in livers and spleens were determined at 3 dpi using RT-qPCR through the standard curve method, after the treatments of 20 or 40 mg/kg Salvianolic acid A (SAA) via i.g., i.p., or i.v., or the treatment of 300 mg/kg T-705 or 30 mg/kg RBV via i.g once daily for 3 days in Female BALB/c mice aged 6–8 weeks.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]; Metabolic kinetic data of Salvianolic acid A (SAA) in rats (n = 3) were determined through both i.g. and i.v. administration routes. The table presents the half-life (t1/2), maximum concentration time (Tmax), maximum blood concentration (Cmax), area under curve (AUC), and bioavailability (F) of SAA across various administration methods.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Sep 3. [Abstract]; The inhibitory effect of Salvianolic acid A (SAA; 5.6, 17, 50 μM) on the cleavage of LCMV CEN on ssRNA substrate was examined at 5, 10, and 20 min via acrylamide-urea gel electrophoresis. Gray analysis of the corresponding strips was calculated for the inhibition rate, shown in the right panel. The divalent metal ion chelator, EDTA, was used as a positive control.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Aug 6. [Abstract]; Viability of RAW264.7 cells tested by CCK-8 assay after treatment with the indicated dose of Salvianolic acid A (SAA; 0-100 μM) for 72 h.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Aug 6. [Abstract]; BMMs tested by CCK‐8 assay after treatment with the indicated dose of Salvianolic acid A (SAA; 0-100 μM) for 120 h.

: Salvianolic acid A purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Aug 6. [Abstract]; Images of TRAcP staining demonstrating that Salvianolic acid A (SAA; 10, 20, 30 μM) dose-dependently inhibited 3-day osteoclastogenesis of RAW264.7 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

Biological Activity
Purity & Documentation
References
Customer Review

Description

Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.

IC₅₀ & Target

MMP-9

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	CC₅₀	86 μM Compound: 7	Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 12 days by WST-1 assay Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 12 days by WST-1 assay	[PMID: 37216809]
MOLM-13	IC₅₀	2.5 μM Compound: 13	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	6.2 μM Compound: 13	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MV4-11	IC₅₀	> 10 μM Compound: 13	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]

In Vivo

A significant beneficial effect of Salvianolic acid A (SAA) is observed in the Salvianolic acid A treatment groups. Salvianolic acid A (20 mg/kg) could significantly prolonged the retention time of rats on the plate. While compared with sham operation group, the brain water content in model group significantly increases, which is attenuated significantly by Salvianolic acid A (10 and 20 mg/kg). Compared with the model group, Salvianolic acid A (5, 10, and 20 mg/kg) could maintain the normal structures of neurons and increase neurons number. It is also found that Salvianolic acid A (20 mg/kg) could significantly reduce I/R induced MMP-9 upregulation. While the MMP-2 expression is not significantly affected by Salvianolic acid A. Tissue inhibitors of metalloproteinases (TIMPs) could inhibit the activity of MMPs through high affinity binding to MMPs catalytic domain^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

494.45

Formula

C₂₆H₂₂O₁₀

CAS No.

96574-01-5

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=CC=C(/C=C/C(O[C@@H](C(O)=O)CC2=CC(O)=C(O)C=C2)=O)C(/C=C/C3=CC(O)=C(O)C=C3)=C1O

Structure Classification

Stilbenes

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL (168.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0224 mL	10.1122 mL	20.2245 mL
5 mM	0.4045 mL	2.0224 mL	4.0449 mL
10 mM	0.2022 mL	1.0112 mL	2.0224 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (4.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.17 mg/mL (4.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Saline
Solubility: 20 mg/mL (40.45 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.72%

Select Batch:

Data Sheet (276 KB) SDS (394 KB)

COA (252 KB) HNMR (143 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Zhang W, et al. Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation. Chin J Nat Med. 2018 Mar;16(3):184-193. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0224 mL	10.1122 mL	20.2245 mL	50.5612 mL
	5 mM	0.4045 mL	2.0224 mL	4.0449 mL	10.1122 mL
	10 mM	0.2022 mL	1.0112 mL	2.0224 mL	5.0561 mL
	15 mM	0.1348 mL	0.6741 mL	1.3483 mL	3.3707 mL
	20 mM	0.1011 mL	0.5056 mL	1.0112 mL	2.5281 mL
	25 mM	0.0809 mL	0.4045 mL	0.8090 mL	2.0224 mL
	30 mM	0.0674 mL	0.3371 mL	0.6741 mL	1.6854 mL
	40 mM	0.0506 mL	0.2528 mL	0.5056 mL	1.2640 mL
	50 mM	0.0404 mL	0.2022 mL	0.4045 mL	1.0112 mL
	60 mM	0.0337 mL	0.1685 mL	0.3371 mL	0.8427 mL
	80 mM	0.0253 mL	0.1264 mL	0.2528 mL	0.6320 mL
	100 mM	0.0202 mL	0.1011 mL	0.2022 mL	0.5056 mL